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Despite excellent vaccine coverage in developed countries, whooping cough is a reemerging disease that can
be caused by two closely related pathogens, Bordetella pertussis and B. parapertussis. The two are antigenically
distinct, and current vaccines, containing only B. pertussis-derived antigens, confer efficient protection against
B. pertussis but not against B. parapertussis. B. pertussis does not express the O antigen, while B. parapertussis
retains it as a dominant surface antigen. Since the O antigen is a protective antigen for many pathogenic
bacteria, we examined whether this factor is a potential protective antigen for B. parapertussis. In a mouse
model of infection, immunization with wild-type B. parapertussis elicited a strong antibody response to the O
antigen and conferred efficient protection against a subsequent B. parapertussis challenge. However, immuni-
zation with an isogenic mutant lacking the O antigen, B. parapertussis wbm, induced antibodies that recog-
nized other antigens but did not efficiently mediate opsonophagocytosis of B. parapertussis. The passive transfer
of sera raised against B. parapertussis, but not B. parapertussis wbm, reduced B. parapertussis loads in the lower
respiratory tracts of mice. The addition of 10 g of purified B. parapertussis lipopolysaccharide (LPS), which
contains the O antigen, but not B. parapertussis wbm LPS drastically improved the efficacy of the acellular
vaccine Adacel against B. parapertussis. These data suggest that the O antigen is a critical protective antigen
of B. parapertussis and its inclusion can substantially improve whooping cough vaccine efficacy against this
pathogen.
Bordetella pertussis and B. parapertussis are the causative
agents of whooping cough, resulting in approximately 50 mil-
lion cases and 300,000 deaths annually worldwide (28). While
whooping cough is considered by the CDC to be a reemerging
disease (5), the relative incidences of B. pertussis and B. para-
pertussis are not clear (50). It is known, however, that the
resurgence of whooping cough roughly correlates with the in-
troduction of acellular pertussis vaccines (5). These vaccines
contain only B. pertussis-derived antigens and confer little to no
protection against B. parapertussis (9, 14, 15, 23, 27, 28). Cur-
rent acellular pertussis vaccines contain some combination of
filamentous hemagglutinin, pertactin, and fimbriae 2 and 3, all
of which are expressed by both B. pertussis and B. parapertussis,
and pertussis toxin, which is B. pertussis specific (33, 34). Based
on genome sequences, the levels of amino acid sequence
identity between B. pertussis and B. parapertussis filamentous
hemagglutinin, pertactin, and fimbria 2 and 3 proteins are
about 98, 91, 71, and 92% (35), and antibodies raised against
these antigens from B. pertussis cross-react with B. paraper-
tussis (17, 31). However, immunization with purified B. per-
tussis filamentous hemagglutinin or pertactin does not con-
fer protection against B. parapertussis (17). B. pertussis
fimbriae confer some protection against B. parapertussis, but
at much lower levels than they protect against B. pertussis
(52). Based on these observations and the fact that B. para-
pertussis infection induces protective immunity to itself (56, 58),
we hypothesized that the lack of protective antigens from B.
parapertussis may be part of the reason why current whooping
cough vaccines are ineffective against this bacterium.
Although B. pertussis and B. parapertussis are very closely
related (8, 35, 48), they differ in the structure of their lipopoly-
saccharides (LPS) (1, 2, 39, 40, 47). B. pertussis produces a
lipooligosaccharide containing lipid A and a branched-chain
core oligosaccharide with a complex trisaccharide modification
but lacks the O antigen due to a natural deletion of the wbm
locus responsible for its synthesis (39, 47). B. parapertussis LPS
is similar to B. pertussis LPS but lacks the trisaccharide modi-
fication and includes an O antigen (39, 40). In addition to
conferring serum resistance by inhibiting C3 deposition onto the
surfaces of bacteria (11), the O antigen enables B. parapertussis to
avoid B. pertussis-induced immunity by preventing antibody bind-
ing to cross-reactive antigens on the surfaces of B. parapertussis
cells (56, 59). Since the O antigen is one dominant surface antigen
recognized by B. parapertussis immune sera (56) and has been
shown previously to be a protective antigen of various pathogenic
bacteria (22, 36), we hypothesized that the O antigen is a protec-
tive antigen of B. parapertussis.
To assess the role of the O antigen in the generation of an
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adaptive immune response to B. parapertussis, the immunity
and protection generated by B. parapertussis infection or vac-
cination were compared to those generated by an isogenic
mutant of B. parapertussis lacking the O antigen (wbm) (39).
Animals immunized with B. parapertussis, but not B. paraper-
tussis wbm, were protected against subsequent challenge with
B. parapertussis. Mice immunized with B. parapertussis wbm
were also deficient in the production of B. parapertussis-specific
antibodies, and sera collected from these mice were less effec-
tive at reducing B. parapertussis colonization upon passive
transfer than sera raised against B. parapertussis. The inclusion
of LPS from B. parapertussis, but not from B. parapertussis
wbm, rendered the acellular B. pertussis vaccine Adacel effi-
cacious against B. parapertussis challenge. Together, these data
indicate that the O antigen is an important protective antigen
of B. parapertussis.
MATERIALS AND METHODS
Bacterial strains and growth. B. pertussis strain 536, B. parapertussis strain
CN2591, and the isogenic B. parapertussis mutant strain lacking the O antigen,
CN2591 wbm, have been described previously (39, 46). For opsonization, at-
tachment, and phagocytosis experiments, these strains were transformed with
plasmid pCW505 (kindly supplied by Alison Weiss, Cincinnati, OH), which
induces cytoplasmic expression of green fluorescent protein (GFP) without af-
fecting growth or antigen expression (51). Bacteria were maintained on Bordet-
Gengou agar (Difco) supplemented with 10% sheep blood (Hema Resources)
and 20 g/ml streptomycin (Sigma-Aldrich). Liquid cultures were grown over-
night on a roller drum at 37°C to mid-log phase in Stainer-Scholte broth (44, 49).
Cells. Peripheral blood polymorphonuclear leukocytes (PMNs) were isolated
from heparinized venous blood by using Ficoll-Histopaque (Sigma, St. Louis,
MO) gradient centrifugation. PMNs were harvested, and the remaining eryth-
rocytes were removed by hypotonic lysis. Cell viability was 99% as determined
by trypan blue exclusion. Prior to functional assays, PMNs were washed twice
with Dulbecco’s modified Eagle medium (HyClone) supplemented with 10%
fetal calf serum (HyClone) and resuspended, and the cells were used immedi-
ately. All experiments were carried out with freshly isolated PMNs lacking FcRI
(CD64) expression, as monitored by fluorescence-activated cell sorter analysis
using a FACScan flow cytometer (Becton Dickinson, San Jose, CA) with anti-
FcRI monoclonal antibody 22 (41).
Opsonization. GFP-expressing strains were opsonized by incubation at 37°C
for 30 min in a final volume of 50 l containing 5% heat-inactivated serum
samples from naïve C3/ mice or convalescent C3/ mice challenged with
CN2591 or CN2591 wbm. Serum-opsonized bacteria were incubated with R-
phycoerythrin (RPE)-labeled goat F(ab)2 fragments of anti-mouse immuno-
globulin G (IgG; Southern Biotechnology, Birmingham, AL) for 30 min at 4°C.
The opsonization of each strain was assessed by fluorescence-activated cell sorter
analysis (43).
Attachment and phagocytosis. Attachment and phagocytosis of the B. para-
pertussis strains were evaluated as described previously, with a few modifications
(42). Briefly, serum-opsonized, GFP-expressing bacteria were subsequently in-
cubated with PMNs at a multiplicity of infection of 30 for 20 min at 37°C to allow
binding. In selected experiments, 200 ng/ml cytochalasin D (Sigma-Aldrich) was
added to inhibit phagocytosis. After extensive washing to remove unattached
bacteria, an aliquot was maintained on ice to be used as a bacterial attachment
control. Another aliquot was further incubated for 1 h at 37°C to allow inter-
nalization. Phagocytosis was stopped by placing PMNs on ice. Cell surface-bound
bacteria in both aliquots (obtained before and after 1 h of incubation at 37°C)
were detected by incubation with RPE-labeled goat F(ab)2 fragments of anti-
mouse IgG at 4°C for 30 min. To avoid eventual cytophilic binding of antibodies,
all incubations were done in the presence of 25% heat-inactivated human serum.
After being washed, samples were analyzed by flow cytometry. Ten thousand
cells per sample were analyzed. Green fluorescence intensity associated with
PMNs maintained at 37°C for 20 min was determined to indicate the level of
bacterial attachment. The decrease in red fluorescence after incubation for 1 h at
37°C reflects bacterial phagocytosis. Phagocytosis was calculated from the drop
in the mean red fluorescence intensity of green fluorescence-positive cells as
described previously (42).
Animal experiments. C57BL/6 mice were obtained from Jackson Laboratories.
C3/ mice were kind gifts from Rick Wetsel and have been described elsewhere
(7). All mice were bred in our Bordetella-free, specific-pathogen-free breeding
rooms at The Pennsylvania State University. Four- to six-week-old mice were
sedated with 5% isoflurane (Abbott Laboratory) in oxygen and inoculated by
pipetting of 50 l of phosphate-buffered saline (PBS; Omnipur) containing 5 
105 CFU of bacteria onto the external nares (18). This method reliably distrib-
utes the bacteria throughout the respiratory tract (13). For rechallenge experi-
ments, mice were treated with gentamicin in drinking water (10 mg/ml) for 7 days
starting on day 21 postinoculation (57). Mice were challenged with 5  105 CFU
of bacteria on day 30 postinoculation and dissected 3 days postchallenge (57).
For passive transfer of sera, 200-l serum samples (collected on day 28 postin-
oculation) from naïve or convalescent C3/ mice were intraperitoneally (i.p.)
injected at the time of inoculation (19, 38). For vaccination, mice were i.p.
injected with 108 CFU of heat-killed CN2591 or CN2591 wbm in 200 l of PBS
with Imject Alum adjuvant (Pierce) on days 0 and 14. For acellular B. pertussis
vaccinations, mice were i.p. injected with one-fifth of a human dose of Adacel
(Sanofi Pasteur; 0.5 g of pertussis toxin, 1 g of filamentous hemagglutinin, 0.6
g of pertactin, and a 5-g mixture of fimbriae 2 and 3 per mouse) in a 200-l
volume containing PBS and Imject Alum adjuvant with or without 10 g of
purified CN2591 LPS or CN2591 wbm LPS (45) on days 0 and 14. Vaccinated
mice were challenged with bacteria on day 28. Mice were sacrificed via CO2
inhalation, and the lungs, tracheae, and nasal cavities were excised. Tissues were
homogenized in PBS, serially diluted, and plated onto Bordet-Gengou agar, and
colonies were counted after incubation at 37°C for 3 to 4 days (25). All protocols
were reviewed and approved by The Pennsylvania State University Institutional
Animal Care and Use Committee, and all animals were handled in accordance
with institutional guidelines.
Splenocyte restimulations. Spleens were taken from C57BL/6 mice immunized
with CN2591 or CN2591wbm on day 28 postinoculation. Splenocytes were isolated
as described previously (25, 37). In brief, spleens were homogenized and red blood
cells were lysed by 0.84% ammonium chloride treatment. Aliquots of cells (2 106)
were resuspended in Dulbecco’s modified Eagle medium supplemented with 10%
fetal calf serum, 1 mM sodium pyruvate (HyClone), and 100 g/ml penicillin-
streptomycin (HyClone) and placed into each well of a 96-well tissue culture plate.
Splenocytes were stimulated with either medium alone or medium containing 107
CFU of heat-killed CN2591 or CN2591 wbm (multiplicity of infection of 5) (37).
After 3 days, the supernatants were collected and analyzed for gamma interferon
(IFN-) and interleukin-10 (IL-10) production via enzyme-linked immunosorbent
assays (ELISAs) per the instructions of the manufacturer (R&D Systems).
Titer ELISAs. Antibody titers were determined as described previously (25,
56). In brief, exponential-phase live CN2591 or CN2591 wbm bacteria were
diluted to 5  107 CFU/ml in a 1:1 mix of 0.2 M sodium carbonate and 0.2 M
sodium bicarbonate buffers. The wells of 96-well plates were coated with these
antigens, and the plates were incubated for 2 h at 37°C in a humidified chamber
and then washed and blocked. Serum samples from individual mice were diluted
1:50, added to the first wells of the plates, and serially diluted 1:2 across the
plates, and the plates were incubated for 2 h at 37°C. Plates were washed, probed
with a 1:4,000 dilution of goat anti-mouse Ig horseradish peroxidase-conjugated
antibodies (Southern Biotech) for 1 h, and washed again prior to visualization
with 2,2-azinobis(3-ethylbenzthiazoline-6-sulfonic acid) diammonium salt in
phosphate-citrate buffer with hydrogen peroxide at an absorbance of 405 nm.
Titers were determined via the end point method based on optical densities in
identically treated wells probed with naïve sera.
Western blot analysis. Lysates containing 107 CFU of heat-killed CN2591 or
CN2591 wbm were run on 10% sodium dodecyl sulfate-polyacrylamide gel
electrophoresis gels under denaturing conditions. Polyvinylidene difluoride
membranes (Millipore) were probed overnight with either naïve sera or sera
from CN2591- or CN2591 wbm-inoculated mice at a 1:500 dilution. Goat
anti-mouse Ig horseradish peroxidase-conjugated antibodies (Southern Biotech)
were used at a dilution of 1:10,000 as the detector antibody (56, 57). The
membrane was visualized with enhanced chemiluminescence Western blotting
detection reagent (Pierce Biotechnology).
Statistical analysis. The mean  standard error was determined for all ap-
propriate data. Two-tailed, unpaired Student’s t tests were used to determine the
statistical significance of differences between groups. All experiments were per-
formed at least twice with similar results.
RESULTS
The O antigen is required for efficient generation of protec-
tive immunity against B. parapertussis infection. To determine
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whether the O antigen contributes to the generation of B.
parapertussis infection-induced protective immunity against
secondary challenge, mice were intranasally inoculated with
either B. parapertussis or B. parapertussis wbm and challenged
with either B. parapertussis or B. parapertussis wbm. Naïve
animals challenged with wild-type B. parapertussis had mean
loads of 106.2, 106.1, and 106.7 CFU in the nasal cavity, trachea,
and lungs on day 3 postchallenge (Fig. 1, black bars). Mice
previously inoculated with B. parapertussis were substantially
immune to subsequent challenge, harboring approximately 103
CFU in the nasal cavity, and had cleared the bacteria from
both the trachea and lungs by 3 days postchallenge (Fig. 1,
white bars). Prior infection with B. parapertussis and B. para-
pertussis wbm conferred similar levels of protection in the
lower respiratory tract (LRT) against subsequent B. paraper-
tussis wbm challenge (Fig. 1, right). Interestingly, B. paraper-
tussis infection induced more protection against the O-antigen-
deficient strain in the nasal cavity than B. parapertussis wbm
infection did (Fig. 1, top right). However, mice immunized
with B. parapertussis wbm harbored at least 8,000-fold more
B. parapertussis bacteria in the lungs, 104.9 CFU, than B. para-
pertussis-immunized mice (P 	 0.01) (Fig. 1, bottom), indicat-
ing that the mutant lacking the O antigen did not induce
effective protective immunity.
Effective vaccine-induced immunity requires a response
against the O antigen. B. parapertussis wbm is known to
colonize at a lower level than B. parapertussis in the presence of
complement (11), raising the possibility that its defect in col-
onization contributes to the decreased protection against sub-
sequent challenge (Fig. 1). To deliver equivalent amounts of
antigens, mice were vaccinated with heat-killed B. parapertussis
or B. parapertussis wbm. Sham-vaccinated control mice chal-
lenged with B. parapertussis harbored 106.4, 105.8, and 106.8
CFU in the nasal cavity, trachea, and lungs 3 days later (Fig. 2,
black bars). Vaccination with B. parapertussis effectively de-
creased B. parapertussis numbers by 99.99% in the LRT and by
80% in the nasal cavity (Fig. 2, white bars). Although vaccina-
tion with B. parapertussis wbm reduced B. parapertussis num-
bers in the LRT (Fig. 2, striped bars), animals vaccinated with
B. parapertussis wbm had 160-, 16-, and 3-fold more bacteria
in the lungs, trachea, and nasal cavity than B. parapertussis-
vaccinated animals (Fig. 2). This decreased protection con-
ferred by B. parapertussis wbm vaccination further strength-
ens the conclusion that the O antigen is required for the
efficient generation of an adaptive immune response against B.
parapertussis.
The O antigen is not required for the development of splenic
IFN- and IL-10 responses to B. parapertussis. Since the O
antigen contributes to the generation of efficient protective
immunity against B. parapertussis, we investigated whether the
O antigen is involved in the generation of a T-cell response.
Splenocytes from naïve or B. parapertussis- or B. parapertussis
wbm-vaccinated mice were stimulated with medium alone or
with heat-killed B. parapertussis or B. parapertussis wbm, and
3 days later, IFN- and IL-10 concentrations in the culture
supernatants were measured. Vaccination with either strain
resulted in increased IFN- and IL-10 production. There was
no significant difference in IFN- or IL-10 production in re-
sponse to B. parapertussis or B. parapertussis wbm between
mice vaccinated with B. parapertussis and those vaccinated with
FIG. 1. The O antigen contributes to the generation of protective
immunity to B. parapertussis. Groups of four C57BL/6 mice were in-
oculated with B. parapertussis (Bpp) or B. parapertussis wbm
(Bppwbm) and allowed to convalesce. Naïve and immunized mice
were challenged with the indicated bacteria. The numbers of CFU
recovered from the nasal cavities, tracheae, and lungs at day 3 post-
challenge are expressed as the log10 means  the standard errors. 
indicates a P value of 0.05 for comparison to results for naïve mice;
‡‡ indicates a P value of 0.01. The limit of detection is indicated by
the y axis.
FIG. 2. A response against the O antigen contributes to effective
vaccine-induced immunity. Groups of four C57BL/6 mice were vacci-
nated with adjuvant only, B. parapertussis with adjuvant (Bpp), or B.
parapertussis wbm with adjuvant (Bppwbm) and challenged with B.
parapertussis. The numbers of CFU recovered from the nasal cavities,
tracheae, and lungs at day 3 postchallenge are expressed as the log10
means  the standard errors.  indicates a P value of 0.05 for
comparison to results for mice vaccinated with adjuvant only; ‡‡ indi-
cates a P value of 0.01. The limit of detection is indicated by the y
axis.
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B. parapertussis wbm (Fig. 3). Since the splenic IFN- and
IL-10 responses are T-cell dependent (D. N. Wolfe, M. J.
Kennett, S. E. Hester, and E. T. Harvill, unpublished data),
these data suggest that the O antigen is not required for the
generation of a T-cell response to B. parapertussis.
The O antigen is required for the generation of an efficient
antibody response against B. parapertussis. As the O antigen is
required for the generation of anamnestic immunity to B.
parapertussis but not an efficient T-cell response, we assessed
whether the O antigen contributes to efficient antibody gener-
ation. In ELISAs using either strain as the antigen, B. para-
pertussis immune serum had significantly less recognition of the
O antigen mutant than of wild-type bacteria (Fig. 4A, left). B.
parapertussis wbm immunization sera had similar Ig titers
when probed with the wild-type and O antigen mutant B.
parapertussis strains (Fig. 4A, right). Sera raised against B.
parapertussis wbm showed a 44% reduction in B. parapertus-
sis-specific antibody titers compared to those in sera raised
against B. parapertussis (Fig. 4A, first and third bars). These
data suggest that vaccination with B. parapertussis induces a
robust antibody response against the O antigen and that vac-
cination with B. parapertussis wbm induces an antibody re-
sponse to other antigens that are shared.
To compare the antigens recognized by sera from different
groups, Western blotting analyses were performed with lysates
of B. parapertussis and B. parapertussis wbm probed with naïve
sera or B. parapertussis or B. parapertussis wbm immune sera
(Fig. 4B). Naïve sera appeared to minimally bind antigens from
either lysate (Fig. 4B, lanes 1 and 2). B. parapertussis-induced
serum antibodies recognized a broad band or smear, band i,
present in B. parapertussis lysate but not in B. parapertussis
wbm lysate (Fig. 4B, lanes 3 and 4), suggesting that it repre-
sents LPS containing the O antigen and that the O antigen is
one of the dominant antigens of B. parapertussis. Several high-
er-molecular-mass antigens shared by the two strains, for
example, those represented by bands iii and iv, were also rec-
ognized by B. parapertussis immune serum antibodies. Inter-
estingly, although B. parapertussis wbm-induced serum anti-
bodies showed recognition of antigen(s) in band iii, these
antibodies lacked recognition of antigen(s) in band iv and had
strong recognition of additional antigen(s) in bands ii and v,
not recognized by B. parapertussis-induced serum antibodies.
As expected, the O antigen (band i) was not recognized by B.
parapertussis wbm-induced serum antibodies. Together, these
FIG. 3. The O antigen is not required for the development of
splenic IFN- or IL-10 responses to B. parapertussis. Splenocytes from
groups of four C57BL/6 mice vaccinated with adjuvant only, B. para-
pertussis with adjuvant (Bpp Vac), or B. parapertussis wbm with ad-
juvant (Bppwbm Vac) were stimulated with the indicated bacteria,
and the resulting IFN- and IL-10 production levels are expressed as
mean concentrations  standard errors.  indicates a P value of 0.05
for comparison to results for medium-stimulated groups. B.p.p., wild-
type B. parapertussis; B.p.p.wbm, B. parapertussis wbm.
FIG. 4. The O antigen contributes to the production of a robust anti-B. parapertussis antibody response. (A) Ig titers in sera from groups of four
C57BL/6 mice immunized with B. parapertussis (B. parapertussis immune sera [B.p.p. IS]) or B. parapertussis wbm (B.p.p.wbm IS) supplemented
with adjuvant were determined via B. parapertussis (B.p.p.)- or B. parapertussis wbm (B.p.p. wbm)-specific ELISAs. Titers are expressed as
means  standard errors.  indicates a P value of 0.05. (B) Lysates (107 CFU) from B. parapertussis (B.p.p.) or B. parapertussis wbm
(B.p.p.wbm) were probed with naïve sera (NS), sera from B. parapertussis-immunized mice (B.p.p. IS), or sera from B. parapertussis wbm-
immunized mice (B.p.p.wbm IS), as indicated. Roman numerals to the right of the gel identify bands.
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data indicate that immunization with B. parapertussis induces a
measurably stronger antibody response, dominated by the O
antigen, than that induced by B. parapertussis wbm and that
immunization with B. parapertussis wbm induces a different
antigen recognition profile from that induced by immunization
with the wild-type counterpart.
The O antigen contributes to the generation of antibodies
that mediate opsonophagocytosis of B. parapertussis by PMNs.
To determine whether antibodies against the O antigen are
important for some key antibody functions, we assessed the
opsonization of bacteria and subsequent attachment to, and
phagocytosis by, PMNs mediated by antibodies raised against
wild-type or O-antigen-deficient B. parapertussis. Because B.
parapertussis wbm is not defective in colonization of mice
lacking complement (11), sera were generated in complement-
deficient mice, thereby removing the difference in bacterial
load as a factor affecting antibody production. Compared to
the naïve sera, B. parapertussis immune sera mediated efficient
opsonization of wild-type B. parapertussis and subsequent at-
tachment to and phagocytosis by PMNs (Fig. 5, middle black
bars). B. parapertussis immune sera were less effective against
O-antigen-deficient B. parapertussis in all three assays (Fig. 5,
middle white bars), suggesting that antibodies recognizing the
O antigen, rather than the shared antigens, are involved. Sera
from mice immunized with O-antigen-deficient B. parapertus-
sis were similarly effective against the wild-type and O-
antigen-deficient strains (Fig. 5, right). Control PMNs
treated with cytochalasin, a phagocytosis inhibitor, showed
no phagocytosis (data not shown), indicating that although
indirect, the assay measured phagocytosis. The observed
high levels of activity of B. parapertussis immune sera against
wild-type but not O-antigen-deficient B. parapertussis sug-
gest that much of this activity is mediated by antibodies to
the O antigen.
The O antigen is required for the generation of antibodies
that efficiently clear B. parapertussis. To determine if the de-
creased B. parapertussis-specific antibody titers of, and op-
sonophagocytosis mediated by, sera raised against B. paraper-
tussis wbm result in decreased antibody-mediated clearance
in vivo, mice received passively transferred naïve sera or sera
raised against wild-type or O-antigen-deficient B. parapertussis
in C3/ mice. Mice were then challenged with B. parapertussis
and sacrificed on day 14 postchallenge for bacterial enumera-
tion, since B. parapertussis poorly stimulates Toll-like receptor
4 (TLR4) and antibodies therefore have no effect until around
day 14 after T cells have been generated (19, 55; D. N. Wolfe,
unpublished data). Naïve sera had no effect on bacterial
loads throughout the respiratory tract on day 14 postchal-
lenge (Fig. 6). As seen in previous studies (19, 56), B. para-
pertussis immune sera decreased the bacterial loads in the
trachea and lungs by 96 and 99.6% at this time point. How-
ever, B. parapertussis wbm immune sera failed to signifi-
cantly reduce B. parapertussis colonization, indicating that
the O antigen is required for the generation of antibodies
that clear B. parapertussis from the LRT in vivo upon adop-
tive transfer. Neither serum treatment affected bacterial
numbers in the nasal cavity.
Supplementing Adacel with B. parapertussis LPS containing
the O antigen confers protection against B. parapertussis chal-
lenge. Since the O antigen is necessary for the generation of
efficient protective immunity to B. parapertussis (Fig. 1, 2, and
4), we examined whether B. parapertussis LPS alone, contain-
ing the O antigen, is sufficient to induce protective immunity
against this pathogen and whether supplementing Adacel with
B. parapertussis LPS renders this vaccine effective against B.
parapertussis. Mice were vaccinated with an adjuvant alone, the
acellular pertussis vaccine Adacel with an adjuvant, or Adacel
with an adjuvant supplemented with purified LPS from B.
parapertussis or B. parapertussis wbm. Vaccination with adju-
FIG. 5. Generation of antibodies that mediate efficient opsono-
phagocytosis of B. parapertussis by PMNs requires the O antigen.
GFP-expressing wild-type B. parapertussis (Bpp) or O-antigen-deficient
B. parapertussis (Bppwbm) was opsonized with naïve sera or sera from
C3/ mice challenged with B. parapertussis (B. parapertussis immune
sera [B.p.p. IS]) or B. parapertussis wbm (B.p.p.wbm IS) and stained
with RPE-labeled goat F(ab)2 fragments of anti-mouse IgG. (A) Op-
sonization levels were measured as mean intensities  standard errors
of red fluorescence from bacteria opsonized with the indicated sera
from four individual mice. (B) Opsonized bacteria were incubated with
freshly isolated human peripheral blood PMNs for 20 min or 1 h and
20 min. Attachment levels were measured as mean intensities  stan-
dard errors of green fluorescence associated with PMNs incubated for
20 min with bacteria opsonized by the indicated sera from four indi-
vidual mice. (C) The cell surface-bound bacteria on PMNs were de-
tected by incubation with RPE-labeled goat F(ab)2 fragments of anti-
mouse IgG. Mean phagocytosis levels  standard errors were
calculated from the drop in red fluorescence of green fluorescence-
positive cells incubated for 1 h and 20 min compared to that of cells
incubated for 20 min. Results were obtained from experiments done
with four independent serum samples. AU indicates arbitrary units; 
indicates a P value of 0.05;  indicates a P value of 0.01.
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vant alone or Adacel had no effect on B. parapertussis loads
throughout the respiratory tract 3 days postchallenge (Fig.
7A). In contrast, vaccination with B. parapertussis LPS, but not
B. parapertussis wbm LPS, significantly reduced B. paraper-
tussis loads in the lungs by 93.8% compared to those in the
group vaccinated with adjuvant alone. Moreover, the addition
of B. parapertussis LPS, but not B. parapertussis wbm LPS, to
Adacel caused significant decreases in bacterial loads, by 70.7,
99.6, and 96.2% in the nasal cavity, trachea, and lungs, respec-
tively, suggesting that the efficacy of an acellular pertussis vac-
cine against B. parapertussis may be increased if B. parapertussis
LPS containing the O antigen is included. To ensure that the
addition of B. parapertussis LPS did not have an impact on the
efficacy of Adacel against B. pertussis, mice were immunized
with this vaccine with or without B. parapertussis LPS and
challenged with B. pertussis. As expected, vaccination with the
adjuvant alone did not affect the colonization by B. pertussis
compared to that of naïve animals (Fig. 7B). Vaccination with
Adacel reduced the B. pertussis load in the lungs by 99.5%
(Fig. 7B, bottom). This vaccine supplemented with B. para-
pertussis LPS caused a similar reduction of B. pertussis numbers
(Fig. 7B, bottom), suggesting that the inclusion of B. paraper-
tussis LPS does not affect the efficacy of the vaccine against B.
pertussis. All together, our data suggest that the addition of B.
parapertussis LPS containing the O antigen to a current acel-
lular vaccine extended its utility to include protective immunity
to B. parapertussis.
FIG. 6. Antibodies to the O antigen are required for efficient an-
tibody-mediated clearance of B. parapertussis. Groups of four C57BL/6
mice were inoculated with B. parapertussis and i.p. injected with the
indicated serum. Bacterial loads in the nasal cavities, tracheae, and
lungs at 14 days postinoculation are expressed as the log10 means 
standard errors.  indicates a P value of0.05 for comparison between
results for groups receiving naïve serum (NS) and B. parapertussis
immune serum. ‡ indicates a P value of0.05 for comparison between
results for groups receiving B. parapertussis wbm immune serum
(B.p.p. wbm IS) and wild-type B. parapertussis immune serum (B.p.p.
IS). The limit of detection is indicated by the y axis.
FIG. 7. Addition of purified B. parapertussis LPS to an acellular B. pertussis vaccine confers protection against B. parapertussis challenge. Groups
of four C57BL/6 mice were vaccinated as indicated and then challenged with B. parapertussis (B.p.p.) (A) or B. pertussis (B.p.) (B) and dissected
at day 3 postchallenge. The numbers of CFU recovered from the nasal cavities, tracheae, and lungs are expressed as the log10 means the standard
errors. ND indicates that CFU were not detectable.  indicates a P value of 0.05. The limit of detection is indicated by the y axis.
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DISCUSSION
A clear picture of B. parapertussis epidemiology is not avail-
able because differential diagnostic methods to distinguish the
two causative agents of whooping cough are rarely performed
at the clinical level and diseases caused by B. parapertussis are
not reportable to the CDC. However, when carefully moni-
tored, B. parapertussis has been found to cause a substantial
proportion of whooping cough cases and even larger propor-
tions among vaccinated groups (4, 23, 24, 50). Although the
mouse model does not replicate coughing symptoms of the
disease, mechanisms of immune control and clearance of
the bordetellae are consistent with what is known of these
mechanisms in humans (19, 29, 30). The data presented here
are consistent with the findings of experimental studies using a
mouse infection model, as well as those of clinical studies, in
which B. pertussis immunity failed to induce protective immu-
nity to B. parapertussis (Fig. 7A) (9, 10, 14, 23, 27, 52, 56, 59).
This work extends the findings of those previous studies to
examine the role of the O antigen in the generation of B.
parapertussis-specific immunity.
We found that although immunization with wild-type B.
parapertussis induced protective immunity to both the wild-
type and the O-antigen-deficient B. parapertussis strains, prior
infection or vaccination with the O-antigen-deficient strain
conferred significantly less protection against the wild type in
the lungs (Fig. 1 and 2). Immunization with B. parapertussis
wbm induced splenic cytokine production similar to that in-
duced by wild-type vaccination (Fig. 3), indicating that the
decrease in protection conferred by the O-antigen-deficient
strain was not due to inefficient T-cell cytokine production.
Interestingly, B. parapertussis-induced antibodies recognized
the O antigen as a dominant antigen (Fig. 4A and B, lanes 3
and 4). Serum antibodies raised against the wild type, but not
the O-antigen-deficient strain, mediated efficient opsono-
phagocytosis and reduced B. parapertussis colonization upon
passive transfer (Fig. 5). Together, these data suggest that the
O antigen is required for the generation of an effective anti-
body response against B. parapertussis.
Antibodies raised against B. parapertussis wbm lacked rec-
ognition of the O antigen but recognized different antigens
from those recognized by antibodies raised against wild-type B.
parapertussis (Fig. 4B) and efficiently cleared B. parapertussis
wbm (Fig. 1). These antigens are present in the B. paraper-
tussis lysate (Fig. 4B), but B. parapertussis wbm immune se-
rum is much less effective at binding live bacteria, mediating
opsonophagocytosis in vitro, or mediating bacterial clearance
in vivo than B. parapertussis immune serum (Fig. 4 to 6), sug-
gesting that these antigens may not be recognized on the sur-
faces of live B. parapertussis cells expressing the O antigen.
These data further indicate that the O antigen is a dominant
surface antigen of B. parapertussis and that antibodies against
it are required for efficient clearance of this bacterium.
The O antigen seems to contribute to the generation of
effective protective immunity against B. parapertussis in the
lungs but not in the trachea or nasal cavity (Fig. 1 and 2).
Wolfe et al. observed that B cells and T cells are required for
clearance of B. parapertussis from the lungs and that CD4
 T
cells, complement, and neutrophils are required for antibody-
mediated clearance in this organ (58). What immune compo-
nents are required for B. parapertussis clearance in the trachea
and nasal cavity is less understood. Infection-induced immu-
nity appeared to be more effective than vaccination-induced
immunity in the nasal cavity and trachea (Fig. 1 and 2). This
pattern may be due to different clearance mechanisms in in-
fection- and vaccination-induced immunity to bordetellae (12).
Vaccination is efficient in controlling disease but may be less
effective in preventing subclinical colonization, as observed
with B. pertussis (28). While the nasal cavity may be a reservoir
of asymptomatic carriage of B. parapertussis, the protection in
the lungs correlates with vaccine efficacy against severe disease
and is thus the focus of this study (9).
The incidence of whooping cough has increased over the
past 20 years, despite the maintenance of excellent vaccine
coverage in developed countries (5). This trend may be due, at
least in part, to vaccines’ being ineffective against B. paraper-
tussis-induced disease (9, 16, 23). Of note, the switch from
whole-cell to acellular vaccines correlates with increased prev-
alence of B. parapertussis (23). Moreover, whooping cough
vaccinations have been proposed to shape the age-incidence
patterns of the two causative agents. B. pertussis is more com-
mon in infants prior to vaccination and adolescents in whom
vaccine-induced immunity has waned (6, 53), whereas B.
parapertussis is most common in young children who have been
recently vaccinated (3, 21, 54; J. Lavine, L. Han, E. T. Harvill,
and O. Bjornstad, unpublished data). All these observations
suggest that current whooping cough vaccines confer a selec-
tive advantage on B. parapertussis in its ongoing competition
with B. pertussis.
We have shown that supplementing the acellular pertussis
vaccine Adacel with 10 g of purified B. parapertussis LPS
containing the O antigen reduced B. parapertussis numbers in
the LRT by more than 90% within 3 days compared to the
numbers in the group receiving Adacel alone (Fig. 7). Thus,
the addition of this single antigen increased the efficacy of this
vaccine against B. parapertussis in the mouse model. These
results are not necessarily easily translated to improved human
vaccines, since vaccine reactogenicity has been associated with
LPS of B. pertussis. However, B. parapertussis LPS is less stim-
ulatory toward TLR4 than B. pertussis LPS, and it is possible to
purify the O antigen portion of the LPS (20, 26, 55), thereby
removing the TLR4 agonist, lipid A, to which is attributed
most of the proinflammatory stimulation (32). Alternatively,
other, as-yet-unidentified antigens of B. parapertussis may
prove to be protective and could be added to acellular whoop-
ing cough vaccines. However, the poor protection conferred by
the O-antigen-deficient strain and the ability of the O antigen
to block the effects of antibodies recognizing other antigens
(56, 59) suggest that the inclusion of the O antigen in the
whooping cough vaccines should be favored over other, as-yet-
unidentified protein antigens.
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